Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Veterinary and Comparative Oncology|June 11, 2013
Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanomaJ S Fowles, C L Denton, D L Gustafson
Cancer Communications|September 1, 1991
Role of xanthine oxidase in the potentiation of doxorubicin-induced cardiotoxicity by mitomycin CD L Gustafson, J D Swanson, C A Pritsos
Oncology Research|January 1, 1997
A new cellular target for mitomycin C: a case for mitochondrial DNAC A Pritsos, L A Briggs, D L Gustafson
Free Radical Research Communications|January 1, 1993
Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapyD L Gustafson, J D Swanson, C A Pritsos
Journal of Veterinary Internal Medicine|October 12, 2011
The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control catsJ M Quimby, D L Gustafson, K F Lunn
Journal of Veterinary Internal Medicine|November 13, 2012
Milk thistle and its derivative compounds: a review of opportunities for treatment of liver diseaseE S Hackett, D C Twedt, D L Gustafson
Journal of Veterinary Pharmacology and Therapeutics|November 8, 2014
Single- and multiple dose pharmacokinetics and multiple dose pharmacodynamics of oral ABT-116 (a TRPV1 antagonist) in dogsS Niyom, K R Mama, D L Gustafson, et al.
Journal of Veterinary Internal Medicine|May 14, 2011
Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphomaE Warry, R J Hansen, D L Gustafson, et al.
Journal of Veterinary Pharmacology and Therapeutics|October 26, 2010
Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young catsJ M Quimby, D L Gustafson, B J Samber, et al.
Pageof 5